Innehållsförteckning
Dawn of a new era in molecular cancer therapeutics.- Obtacles and opportunities in the clinical development of targeted therapeutics.- Tumor models for preclinical development of targeted agents.- Angiogenesis inhibitors: What is the clinical future?.- Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.- Cell survival signaling during apoptosis: Implications in drug resistance and anti-cancer therapeutic development.- Targeted histone deacetylase inhibition for cancer prevention and therapy.- Inhibitors of cyclin-dependent kinase modulators for cancer therapy.- Targeting cyclooxygenase-2 for cancer prevention and treatment.- Antisense approaches in drug discovery and development.- Preclinical development of Alimta™ (Pemetrexed, LY231514), a multitargeted antifolate.